BRCA2 Alterations in Neuroendocrine/Small-Cell Carcinoma Prostate Cancer: A Case Series.

Abstract

Article Tools CASE REPORTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/PO.22.00091 JCO Precision Oncology no. 6 (2022) e2200091. Published online July 14, 2022. PMID: 35834759 BRCA2 Alterations in Neuroendocrine/Small-Cell Carcinoma Prostate Cancer: A Case Series Lynn Symonds , MD1xLynn SymondsSearch for articles by this author; Erik Konnick , MD2xErik KonnickSearch for articles by this author; Funda Vakar-Lopez, MD2xFunda Vakar-LopezSearch for articles by this author; Heather H. Cheng , MD, PhD1,3xHeather H. ChengSearch for articles by this author; Michael T. Schweizer , MD1,3xMichael T. SchweizerSearch for articles by this author; Peter S. Nelson , MD1,2,3,4xPeter S. NelsonSearch for articles by this author; Colin C. Pritchard , MD, PhD2,5xColin C. PritchardSearch for articles by this author; and Bruce Montgomery , MD1,6xBruce MontgomerySearch for articles by this author Show More 1Division of Medical Oncology, University of Washington, Seattle, WA2Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA3Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA4Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA5Brotman Baty Institute for Precision Medicine, Seattle, WA6VA Puget Sound and Precision Oncology Program for Cancer of the Prostate, Seattle, WA https://doi.org/10.1200/PO.22.00091 First Page Full Text PDF Figures and Tables © 2022 by American Society of Clinical OncologySUPPORTSupported by the Pacific Northwest Prostate Cancer SPORE CA097186 (P.S.N., B.M.); Prostate Cancer Foundation Challenge Awards (B.M., P.S.N.); CDMRP Awards W81XWH-18-1-0355 (P.S.N., C.C.P., B.M.), W81XWH-21-1-0264 (P.S.N.), W81XWH-17-2-0043 (H.H.C.), R01 CA234715 (P.S.N.), T32 CA009515 (L.S.).AUTHOR CONTRIBUTIONSConception and design: Peter S. Nelson, Bruce MontgomeryFinancial support: Peter S. NelsonAdministrative support: Bruce MontgomeryProvision of study materials or patients: Funda Vakar-Lopez, Heather H. Cheng, Peter S. Nelson, Colin C. PritchardCollection and assembly of data: Erik Konnick, Funda Vakar-Lopez, Heather H. Cheng, Colin C. Pritchard, Bruce MontgomeryData analysis and interpretation: Lynn Symonds, Erik Konnick, Heather H. Cheng, Michael T. Schweizer, Peter S. Nelson, Colin C. Pritchard, Bruce MontgomeryManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Erik KonnickConsulting or Advisory Role: RocheFunda Vakar-LopezConsulting or Advisory Role: AstraZenecaHeather H. ChengConsulting or Advisory Role: AstraZeneca, AstraZeneca (I)Research Funding: Sanofi (Inst), Janssen (Inst), Clovis Oncology (Inst), Color Genomics Foundation (Inst), Medivation/Astellas (Inst), Phosplatin Therapeutics (Inst)Patents, Royalties, Other Intellectual Property: UpToDateOther Relationship: JanssenMichael T. SchweizerConsulting or Advisory Role: Resverlogix, AstraZeneca, PharmaIn, SanofiResearch Funding: Janssen (Inst), AstraZeneca (Inst), Roche (Inst), Pfizer (Inst), Zenith Epigenetics (Inst), Madison Vaccines, Inc (Inst), Immunomedics (Inst), Bristol Myers Squibb (Inst), Merck (Inst), Tmunity Therapeutics, Inc (Inst), SignalOne Bio (Inst)Peter S. NelsonConsulting or Advisory Role: Janssen Oncology, Astellas Pharma, Roche/Genentech, Bristol Myers SquibbResearch Funding: Genomic Health (Inst)Expert Testimony: VenableTravel, Accommodations, Expenses: Janssen OncologyColin C. PritchardConsulting or Advisory Role: AstraZeneca, Sana BiotechnologyResearch Funding: Color Genomics (I)Bruce MontgomeryResearch Funding: AstraZeneca (Inst), Janssen Oncology (Inst), Clovis Oncology (Inst), Astellas Pharma (Inst), Beigene (Inst)No other potential conflicts of interest were reported.